CTXR - Citius Pharmaceuticals

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, May 15, 2020.

  1. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    828
    Likes Received:
    79
    CTXR Fact Sheet
    May 21, 2021
    https://ir.citiuspharma.com/presentations

    Market Opportunity –Critical Care/Infectious Disease: The market potential for an effective antibiotic lock therapy (“ALT”) is estimated at $750 million per year in the U.S. and is projected to reach $1.84 billion globally in 2028... Mino-Lok has the potential to change the standard of care for the management of these serious infections. M-L Phase III Interim Efficacy Q2 ‘21.

    Market Opportunity – Prescription Hemorrhoid Product: We believe the $2 billion worldwide market...
    CITI-002 –Halo-Lido: ... We expect to file an IND in Q2 2021 and initiate the phase 2b trial in Q3 2021.
     
  2. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    828
    Likes Received:
    79
    Leonard Mazur, Chairman of Citius Pharmaceuticals (NASDAQ:CTXR) Interviewed on CEORoadshow
    June 10, 2021

     
  3. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    828
    Likes Received:
    79
  4. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    828
    Likes Received:
    79

Share This Page